Keyword: Farxiga

J&J scored a win for Invokana in September with an FDA OK to treat kidney disease. Now, as a newcomer to the field, J&J is seeking marketing backup.

AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.

AstraZeneca is touting SGLT2 med Farxiga’s cardiovascular outcomes win as a game changer for the market. Turns out the FDA likes those results, too.

Now that AstraZeneca has scored its Farxiga outcomes data, it's beefing up its sales team to prepare for an expanded FDA approval.

AstraZeneca's Farxiga has new CV data that could help the entire SGLT2 class—and even pressure heart medicines outside the class, too. 

AstraZeneca is on its way to scoring a key new nod for SGLT2 diabetes drug Farxiga, and the FDA just sped things up.

AstraZeneca is still stinging after its SGLT2 drug Farxiga was waved off in Type 1 diabetes, but new heart failure data could ease the pain.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Boehringer Ingelheim Eli Lilly’s Jardiance is going after an indication in chronic heart failure—and the FDA just sped up the process.